Samsung Biologics, a leading CDMO, today launched Samsung Organoids, a cutting‑edge drug screening platform designed to accelerate drug discovery and predict patient responses more accurately.
Introducing Samsung Organoids
Samsung Organoids employs three‑dimensional cell culture systems that faithfully replicate human organ structures. By mimicking live tissues, these organoids deliver clinically relevant insights into drug efficacy, safety, and biomarker identification—insights that traditional two‑dimensional assays often miss.
Harnessing Organoid Technology for Precision Screening
Moreover, Samsung Organoids enables precision screening of candidate molecules:
*Predicting patient responses to tailor therapies early.
*Streamlining preclinical development through data‑driven analysis.
*Accelerating IND filings by flagging potential liabilities sooner.
Expanding into Preclinical Research
With this launch, Samsung Biologics broadens its service portfolio to cover the entire preclinical landscape, including:
*Target Discovery
*Lead Selection
*Preclinical Development
*Clinical Trial Planning
Leveraging its manufacturing expertise, the company will now provide multi‑modal insights into molecular mechanisms, helping clients overcome challenges during lead optimization and beyond.
Enhancing Clinical Success Rates
By integrating organoid technology into its offerings, Samsung Biologics aims to boost clinical success rates and reduce late‑stage failures. “This latest service launch reflects our unwavering commitment to driving innovation and creating new possibilities in personalized medicine,” said John Rim, CEO and President of Samsung Biologics.
Driving Personalized Medicine Forward
As reported by pharmabiz.com, furthermore, Samsung Organoids positions Samsung Biologics as a full‑cycle partner—supporting clients from early therapeutic analysis to large‑scale manufacturing—and underscores the company’s mission to deliver safer, more effective therapies to patients worldwide.